Toboroz
A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
NCT07623161· 3. fázis· Takeda· Forrás
Contact: Mark Faber (principal investigator)
Toboroz
A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia
NCT07623200· 3. fázis· Incyte Corporation· Forrás
Toboroz
A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Lower Risk Myelodysplastic Syndromes (LR-MDS) Who Need Regular Blood Transfusions
NCT07422480· 3. fázis· Takeda· Forrás
Contact: Mark Faber (principal investigator)
Toboroz
DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma
NCT07288112· 1/2. fázis· Diakonos Oncology Corporation· Forrás
Contact: Mayra Madrid
Fut, nem toboroz
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
NCT07266441· 2. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
NCT07280013· 1. fázis· C4 Therapeutics, Inc.· Forrás
Contact: Study Medical Officer
Toboroz
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
NCT07188558· 3. fázis· Lyell Immunopharma, Inc.· Forrás
Contact: James Dean, MD, PhD
Toboroz
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
NCT07222800· 3. fázis· Pfizer· Forrás
Toboroz
Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial
NCT07061964· 2. fázis· National Cancer Institute (NCI)· Forrás
Contact: Chinedu Mmeje (principal investigator)
Fut, nem toboroz
Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen
NCT07087054· 3. fázis· Crinetics Pharmaceuticals Inc.· Forrás
Toboroz
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
NCT07007312· 3. fázis· Kura Oncology, Inc.· Forrás
Toboroz
Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
NCT06814496· 1/2. fázis· University of Arizona· Forrás
Contact: Ravinder Clayton, MD
Toboroz
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
NCT06982521· 3. fázis· Relay Therapeutics, Inc.· Forrás
Contact: Relay Therapeutics, Inc
Toboroz
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
NCT06958328· 3. fázis· NRG Oncology· Forrás
Contact: Gary V. Walker (principal investigator)
Toboroz
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
NCT07062965· 3. fázis· Pfizer· Forrás
Toboroz
Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy
NCT07000084· 3. fázis· Alliance for Clinical Trials in Oncology· Forrás
Contact: Chinedu Mmeje (principal investigator)
Fut, nem toboroz
A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer
NCT06966453· 1/2. fázis· Pfizer· Forrás
Fut, nem toboroz
Alpha Radiation Emitters (DaRT) With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer
NCT06698458· Alpha Tau Medical LTD.· Forrás
Toboroz
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
NCT06682793· 1/2. fázis· A2 Biotherapeutics Inc.· Forrás
Contact: Kylie Ketchum
Toboroz
DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)
NCT06805305· 2. fázis· Diakonos Oncology Corporation· Forrás
Toboroz
Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
NCT06784193· 1. fázis· Olema Pharmaceuticals, Inc.· Forrás
Contact: There may be multiple sites in this clinical trial Olema Clinical Trial Lead
Toboroz
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
NCT06750094· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
NCT06662786· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
NCT06625320· 3. fázis· Revolution Medicines, Inc.· Forrás
Toboroz
Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
NCT06567743· 2. fázis· CG Oncology, Inc.· Forrás
Contact: Chinedu Mmeje, MD
Toboroz
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
NCT06246916· 3. fázis· Regeneron Pharmaceuticals· Forrás
Contact: Clinical Trials Administrator
Fut, nem toboroz
A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
NCT06413498· 3. fázis· Kite, A Gilead Company· Forrás
Meghívásos bevonás
Long-term Follow-up of Gene Therapy for Radiation-Induced Xerostomia
NCT06544798· 2. fázis· MeiraGTx, LLC· Forrás
Toboroz
VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]
NCT06264180· 3. fázis· Replimune, Inc.· Forrás
Contact: Fade Mahmoud, MD, FACP (principal investigator)
Toboroz
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
NCT06500273· 2. fázis· Allogene Therapeutics· Forrás
Contact: Matthew Ulrickson, MD (principal investigator)
Fut, nem toboroz
A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT06425991· 1. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
NCT06479135· 3. fázis· Kartos Therapeutics, Inc.· Forrás
Contact: John Mei
Toboroz
Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
NCT06116110· Miltenyi Biomedicine GmbH· Forrás
Contact: Yasmin Adam
Toboroz
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
NCT05863195· 3. fázis· ECOG-ACRIN Cancer Research Group· Forrás
Contact: Rajesh Ramanathan (principal investigator)
Fut, nem toboroz
RRx-001 for Reducing Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer
NCT05966194· 2. fázis· EpicentRx, Inc.· Forrás
Toboroz
A Clinical Study of MK-4208/TERN-701 in Participants With Chronic Myeloid Leukemia (CML) (MK-4208-003/Tern701-1012/CARDINAL)
NCT06163430· 1/2. fázis· Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)· Forrás
Contact: Toll Free Number
Toboroz
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
NCT06297226· 2. fázis· Juno Therapeutics, Inc., a Bristol-Myers Squibb Company· Forrás
Contact: Ambuga Badari, Site 0025
Toboroz
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
NCT06001788· 1. fázis· Kura Oncology, Inc.· Forrás
Toboroz
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
NCT06162221· 1/2. fázis· Revolution Medicines, Inc.· Forrás
Contact: Revolution Medicines
Toboroz
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
NCT06064877· 3. fázis· AVEO Pharmaceuticals, Inc.· Forrás
Contact: Clinical Trials Office
Toboroz
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
NCT06119581· 3. fázis· Eli Lilly and Company· Forrás
Contact: Todd Erickson (principal investigator)
Fut, nem toboroz
A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT
NCT06111235· 3. fázis· CG Oncology, Inc.· Forrás
Fut, nem toboroz
Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2
NCT05911295· 3. fázis· Seagen, a wholly owned subsidiary of Pfizer· Forrás
Fut, nem toboroz
A Study of AAV2-hAQP1 Gene Therapy in Participants With Radiation-Induced Late Xerostomia
NCT05926765· 2. fázis· MeiraGTx, LLC· Forrás
Fut, nem toboroz
A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors
NCT05726864· 1/2. fázis· Elicio Therapeutics· Forrás
Fut, nem toboroz
A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
NCT05572515· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 Trial
NCT05411081· 2. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Intravesical BCG vs GEMDOCE in NMIBC
NCT05538663· 3. fázis· ECOG-ACRIN Cancer Research Group· Forrás
Fut, nem toboroz
A Study Investigating the Efficacy and Safety of Alcestobart (LBL-007) Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer
NCT05609370· 1/2. fázis· BeiGene· Forrás
Fut, nem toboroz
Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+)
NCT05546580· 1. fázis· Oryzon Genomics S.A.· Forrás
Showing 50 of 96.